Replication Data for Determinants of early antibody responses to COVID-19 mRNA vaccines in exposed and naïve healthcare workers

Databases containing raw analytical data obtained in the SEROCOV-1 and SEROCOVAC studies and personal covariates used in the publication Moncunill G, Aguilar R, et al EBioMedicine. 2022 Jan 11;75:103805. doi: 10.1016/j.ebiom.2021.103805. Data correspond to antibody levels to SARS-CoV-2 and four seas...

Descripción completa

Detalles Bibliográficos
Autores: Gemma Moncunill, Ruth Aguilar, Marta Ribes, Natalia Ortega, Rocío Rubio, Gemma Salmeron, Maria José Molina, Marta Vidal, Diana Barrios, Robert A. Mitchell, Alfons Jimenez, Cristina Castellana, Pablo Hernández-Luis, Pau Rodó, Susana Méndez, Anna Llupià, Laura Puyol, Natalia Rodrigo Melero, Carlo Carolis, Alfredo Mayor, Luis Izquierdo, Pilar Varela, Antoni Trilla, Anna Vilella, Sonia Barroso, Ana Angulo, Pablo Engel, Marta Tortajada, Alberto L. Garcia-Basteiro, Carlota Dobaño
Tipo de recurso: conjunto de datos
Fecha de publicación:2022
País:España
Institución:Consorci de Serveis Universitaris de Catalunya (CSUC)
Repositorio:CORA.Repositori de Dades de Recerca
OAI Identifier:oai:dnet:cora.rdr____::3dd1714c07fa645d95bbb224811c4c6b
Acceso en línea:https://doi.org/10.34810/DATA175
Access Level:acceso abierto
Palabra clave:Medicine, Health and Life Sciences
mRNA vaccine
SARS-CoV-2
COVID-19
Antibodies, Neutralizing
Antibody Affinity
Health Personnel
Cohort Studies
Descripción
Sumario:Databases containing raw analytical data obtained in the SEROCOV-1 and SEROCOVAC studies and personal covariates used in the publication Moncunill G, Aguilar R, et al EBioMedicine. 2022 Jan 11;75:103805. doi: 10.1016/j.ebiom.2021.103805. Data correspond to antibody levels to SARS-CoV-2 and four seasonal coronaviruses, and the neutralization capacity of samples from 578 participants recruited from 28 March- 9 April 2020, and the follow-up visits after one, three, six, nine and twelve months. In months 9 and 12, data on vaccination status was collected and some participants had already received the 1st (N=64) or the 2nd doses (N=4). Month 12 follow-up mostly included participants who had a blood sample taken two weeks post 2nd dose. The analytical data is completed with participants' information on occupation, comorbidities, previous COVID19 diagnoses and other sociodemographic characteristics. The code was developed using R version 4.0.3.

Similares en LA Referencia